Figure 4
A CaMKII inhibitor KN-93 suppresses tactile allodynia and cPLA 2 activation. (A-C) Immunohistochemical (A, B) and western blot (C) analyses of p-CaMKII and p-cPLA2 proteins in the ipsilateral L5 DRG of KN-92- and KN-93-treated rats 7 days after nerve injury. Arrowheads show DRG neurons positive for both p-CaMKII and p-cPLA2. Scale bar, 50 μm. (D) The number of p-cPLA2-translocated neurons in the ipsilateral L5 DRG 7 days after nerve injury. About 1000 neurons profiles were counted in twenty randomly chosen sections from six rats in each group. Results are percentages (means ± SEM) of p-cPLA2-translocated neurons (p-cPLA2 neurons) relative to the total number of neurons. ***p < 0.001 compared with the KN-92-treated group. (E) Effect of KN-93 on the development of nerve injury-induced tactile allodynia. Results are means ± SEM of the paw withdrawal thresholds on the ipsilateral (ipsi) and contralateral (contra) sides. ***p < 0.001 compared with the threshold on day 0. ##p < 0.01, ###p < 0.001 compared with the threshold of the KN-92-treated group. (F) Effect of a single administration of KN-93 on the decrease in paw withdrawal threshold (mean ± SEM) 7 days after nerve injury. ***p < 0.001 compared with pre-injury baseline (Pre). ###p < 0.001 compared with the threshold on day 7.